Tubulin · PROTEIN COMPLEX GROUP · Taeniidae
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Tubulin shows approved-linked disease relevance led by Helminthiasis. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt C4PKY4. Start with Helminthiasis, then reuse UniProt C4PKY4 as the stable protein anchor across project notes and exports.
Start with Helminthiasis, then reuse UniProt C4PKY4 as the stable protein anchor across project notes and exports.
Tubulin shows approved-linked disease relevance led by Helminthiasis. 5 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.
Start review with Helminthiasis because it currently carries approved-linked support. Linked drugs include ALBENDAZOLE, MEBENDAZOLE, OXFENDAZOLE, THIABENDAZOLE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyBeta-tubulin isoform 1
Review this target as Tubulin, mapped to UniProt C4PKY4. ChEMBL maps the protein component as Beta-tubulin isoform 1. Sequence length is 108 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Tubulin as ChEMBL target CHEMBL2364704, mapped to UniProt C4PKY4. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Tubulin is the right protein anchor across sources, using UniProt C4PKY4 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Helminthiasis is currently framed as approved-linked support. It currently carries 4 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Tubulin |
| Target Type | PROTEIN COMPLEX GROUP |
| Organism | Taeniidae |
| UniProt | C4PKY4 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Beta-tubulin isoform 1 |
| UniProt Accession | C4PKY4 |
| Component Type | Protein |
| Sequence Length | 108 aa |
Beta-tubulin isoform 1
Review this target as Tubulin, mapped to UniProt C4PKY4. ChEMBL maps the protein component as Beta-tubulin isoform 1. Sequence length is 108 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Tubulin shows approved-linked disease relevance led by Helminthiasis. 5 more disease programs remain visible in the same review block.
Start review with Helminthiasis because it currently carries approved-linked support. Linked drugs include ALBENDAZOLE, MEBENDAZOLE, OXFENDAZOLE, THIABENDAZOLE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.